OGon behalf of ARTICO-19 Research Collaborative Group
on behalf of ARTICO-19 Research Collaborative Group
+5
Few studies have focused on arterial thrombosis and acute limb ischemia in COVID-19. This international registry intended to study the spectrum of clinical characteristics, therapeutic trends, and outcomes in a cohort of Ibero-Latin American patients with arterial thrombosis or acute limb ischemia and COVID-19. Data were retrospectively obtained from 21 centers in 9 countries. Patients with proven COVID-19 and asymptomatic or symptomatic arterial thrombosis were included. COVID-19 diagnosis was established by RT-PCR assay or IgM serology plus suggestive clinical/radiographical findings. We recorded and analyzed variables related to demography, clinical presentation, therapeutic trends, and outcomes. Eighty one patients were included in the registry. In 38.3%, acute limb ischemia symptoms were the first manifestation of COVID-19. Non-surgical management was more frequent in severe cases than surgical interventions, 11.1% vs. 88.9%, respectively (p = 0.004). Amputation rates were similar between all COVID severity groups (p = 0.807). Treatment was classified as non-surgical, open surgical, and endovascular treatment. Further analysis revealed an equal frequency of major leg amputation between treatment groups and increased mortality in patients with non-surgical management. However, multivariate regression analysis showed that treatment choices are associated with disease severity, with significant non-surgical treatment in critical patients; thus, mortality is related to the severity and confounds treatment analysis. Arterial thrombosis can be the initial symptom of a patient presenting with COVID-19. Physicians and health workers should potentially suspect COVID-19 in acute ischemia cases without a known risk factor or embolic cause. More experimental and clinical research is required to understand the complex phenomenon of arterial COVID-19 induced coagulopathy fully.
Introdução Atualmente, os ensaios de troponina cardíaca de alta sensibilidade (hs-cTn) estão disponíveis para uso clínico e fazem parte da definição de infarto agudo do miocárdio (IAM). , No entanto, a elevação da troponina não se limita ao IAM, já que outras condições relacionadas ao mismatch da demanda de oxigênio, dano direto ao miocárdio, aumento de strain miocárdico, processos sistêmicos (por ex., sepse), doença neurológica e insuficiência renal também podem resultar em seu aumento. A troponina agora também pode ser [...] Introdução Atualmente, os ensaios de troponina cardíaca de alta sensibilidade (hs-cTn) estão disponíveis para uso clínico e fazem parte da definição de infarto agudo do miocárdio (IAM). , No entanto, a elevação da troponina não se limita ao IAM, já que outras condições relacionadas ao mismatch da demanda de oxigênio, dano direto ao miocárdio, aumento de strain miocárdico, processos sistêmicos (por ex., sepse), doença neurológica e insuficiência renal também podem resultar em seu aumento. A troponina agora também pode ser
31 March 2023 in Archives of Evidence-Based Medicine
COVID-19 and the “new normal” have come here to stay. What initially emerged as a local outbreak transitioned into a global pandemic, and has caused more than 6 million deaths.2 The sudden onset of the SARS-CoV-2 crisis challenged health care systems in terms of both patient overflow and information paucity. As the new infectious agent was previously unknown, evidence was scarce and highly controversial. Nonetheless, after the novel coronavirus continued spreading, medical literature became available to the point that more than 72,000 articles were published in PubMed in 2020 (Figure 1). This number is around 80 times greater than the previous year.